Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY.

Nicole OosteromNiala den BraberGozewijn D Laverman

Published in: Endocrinology, diabetes & metabolism case reports (2022)

HNF4A-MODY has a mild phenotype. Blood glucose was responsive to long-term metformin treatment in HNF4A-MODY. Metformin and gliclazide seem appropriate treatments for HNF4A-MODY.

Keyphrases

blood glucose
nuclear factor
glycemic control
toll like receptor
cancer therapy
immune response
inflammatory response
smoking cessation